Comparative Pharmacology
Head-to-head clinical analysis: ASTELIN versus ASTEPRO ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTELIN versus ASTEPRO ALLERGY.
ASTELIN vs ASTEPRO ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine, a phthalazinone derivative, exerts its effects by competitively inhibiting histamine H1-receptors, stabilizing mast cells, and reducing the release of inflammatory mediators. It also has anti-allergic properties including inhibition of leukotriene synthesis and suppression of eosinophil chemotaxis.
Antihistamine; selectively antagonizes histamine H1 receptors, preventing histamine-mediated allergic responses.
1 spray (137 mcg) per nostril twice daily (total daily dose: 548 mcg).
One spray (205.5 mcg azelastine hydrochloride and 137 mcg fluticasone propionate) per nostril twice daily.
None Documented
None Documented
The terminal elimination half-life of azelastine (active ingredient) is approximately 22 hours, supporting twice-daily dosing.
Terminal elimination half-life is 22-26 hours. Clinical context: supports once-daily dosing; steady state achieved within ~5 days.
Renal excretion accounts for approximately 75% of the administered dose, with about 10% as unchanged drug. Fecal excretion is about 20%.
Primarily renal excretion; approximately 70-80% of a dose is excreted as unchanged drug in urine, with the remainder as metabolites. Fecal elimination accounts for <10%.
Category C
Category C
Antihistamine (Nasal)
Antihistamine (Nasal)